Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m). The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The company anticipates the deal to positively impact operating income from fiscal 2028 onwards, after amortisation of goodwill and intangib

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP) FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, US. This

Feb. 24, 2026 -- Turbine, a leading virtual biology company, today announced a $25 million Series B financing, an expansion of its virtual cell platform across industries and a new immunology-focused partnership with a top 10 pharma company. The Series B round is led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors, including MSD Global Health Innovation, Accel and Mercia. "Central and Eastern Europe has produced exceptional innovation, and Turbine

Dosing of Cohort 1 complete with first three patients having received starting dose of JAG201 delivered via intracerebroventricular (ICV) injection First two patients in dose-escalation Cohort 2 have been dosed, and company anticipates target enrollment and dosing to be completed in Cohort 2 in Q2 2026No treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) have been reported to dateEarly indications of clinical benefit observed in neurodevelopmental domains, incl

Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CBI-1214, the company’s lead investigational therapy targeting LY6G6D in adults with microsatellite stable or microsatellite instability-low (MSS/MSI-L) colorectal cancer (CRC). LY6G6D is selectively expressed in CRC, making it a compelling therapeutic target with

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau Medical Ltd. (Headquarters: Jerusalem, Israel) has received official approval in Japan. HekaBio led the approval process as the Designated Marketing Authorization Holder (DMAH) and will be responsible for launching the product in the Japanese market.With this approval, Japan becomes the first country in the world outside

IntraBio Inc. today announced that a positive opinion recommending Orphan Medicinal Product Designation for Acetylleucine for the treatment of CACNA1A disorders has been granted by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). The European Commission is expected to grant the designation in Q2 2026. CACNA1A-related disorders are rare, genetic neurological conditions characterized by progressive impairment in coordination, balance, speech, and overall

Feb. 23, 2026 -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced today a new research partnership with the University of Louisville that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in three different cancers, including colorectal, liver, and pancreatic. As part of the collaboration, the University of Louisville will be analyzing live

Feb. 25, 2026 -- Abram Scientific, a medical device company focused on advancing next-generation coagulation diagnostics, today announced the closing of a $11.75 million Series A financing round. The round was led by global pharmaceutical leader Octapharma AG, with additional participation from existing and new investors affiliated with University of Colorado Anschutz. This funding will accelerate the development of Abram Scientific's proprietary portable platform, CoagCare™, for aiding the eva

Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagement Results are published in the 7 January issue of the Journal of Inherited Metabolic Disease Nizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today ann